Response to rituximab in children and adults with immune thrombocytopenia (ITP).

ABSTRACT:

Background

Rituximab is a monoclonal anti-CD20 antibody used as a second-line treatment for immune thrombocytopenia (ITP). As additional treatments for ITP emerge, identifying the most appropriate patients and optimal timing for rituximab are important but challenging without established predictors of response to therapy.

Objectives

The purpose of this study was to describe demographic, clinical, and laboratory characteristics of pediatric and adult patients with ITP to identify differences in evaluation before rituximab administration and correlates of platelet response.

Methods

This is a retrospective cohort study describing the characteristics of patients with ITP treated with rituximab from 2010 to 2020 at two academic tertiary care centers.

Results

A total

SUBMITTER: Harris EM 

PROVIDER: S-EPMC8385184 | biostudies-literature | 2021 Aug

REPOSITORIES: biostudies-literature